Core Insights - Apple-related stocks have shown strong performance, with notable increases in share prices for companies such as Highgreat Electronics (5.42%), Q Technology (4.96%), and BYD Electronics (3.46%) [1] Sales Performance - According to Counterpoint Research, the sales of the iPhone 17 series in the first 10 days after launch in China and the US are 14% higher compared to the iPhone 16 during the same period [1] - The base model iPhone 17 has performed particularly well in the Chinese market, while the high-end iPhone 17 Pro Max has seen the strongest demand growth in the US [1] Product Comparison - The new ultra-thin iPhone Air, although targeting a smaller audience and generating less buzz than the base iPhone 17, has already surpassed the sales of the previous "Plus" model it replaced [1]

Group 1 - Bosideng (03998.HK) saw its share price increase by 10.67%, reaching HKD 4.98 [2] - The trading volume for Bosideng amounted to HKD 499 million [2]

Core Viewpoint - The Hang Seng Technology Index continues to strengthen, rising over 3%, while the Hang Seng Index increases nearly 2% [1] Company Performance - Bilibili's stock has surged nearly 10% [1] - Semiconductor Manufacturing International Corporation (SMIC) has seen its stock rise over 5% [1]

Core Viewpoint - Bosideng (03998) has seen a significant increase in stock price, rising by 10.67% to HKD 4.98, with a trading volume of HKD 499 million, driven by favorable weather conditions and positive market analysis [1] Group 1: Weather Impact - The upcoming typhoon "Fengshen" and its peripheral circulation, along with cold air, are expected to bring strong wind and rain to South China and the northern South China Sea [1] - The cold air moving eastward will lead to a drop in temperatures in Jiangnan and South China, creating a favorable environment for winter clothing sales [1] Group 2: Market Analysis - Shenwan Hongyuan has recommended Bosideng, highlighting that the onset of colder weather will directly benefit the company's winter apparel sales [1] - The Spring Festival in 2026 is on February 17, which is 19 days later than the previous year, extending the effective sales window and potentially increasing sales volume [1] - The low base from the warm winter of 2024 is expected to aid in achieving sales targets, while the market is currently favoring high-dividend assets [1] - Bosideng has maintained a dividend payout ratio of 80% or higher, and this trend is expected to continue, supporting the company's performance and valuation growth [1]

Core Viewpoint -津上机床中国 (01651) has seen a significant stock price increase, rising over 10% and reaching a new high of 35.88 HKD, with a year-to-date increase of 200% [1] Financial Performance - For the first half of the fiscal year 2026 (April-September 2025), the company expects to achieve a net profit attributable to shareholders of 502 million RMB, representing a year-on-year increase of approximately 48% [1] - The board attributes the growth in performance to the continuous recovery of the domestic economy and the transformation and upgrading of China's manufacturing industry [1] Industry Trends - The rapid development in user sectors such as new energy vehicles and artificial intelligence has created new demand for the machine tool industry [1] - The company has been actively exploring and penetrating various segments of the manufacturing industry, leading to an increased demand for its CNC high-precision machine tools [1] Market Position - According to CICC, the company's forecasted profit growth of 48% significantly exceeds the average growth level in the industry, positioning it as a core leader in the recovery process of the machine tool industry [1] - The largest downstream sector for the company is automotive parts, benefiting from the capital expenditure boom [1] Growth Opportunities - The company is intensifying its layout in the liquid cooling sector, which is expected to open up a new growth curve [1] - The company has reached a cooperation intention with leading liquid cooling equipment enterprises, anticipating that this business will contribute to revenue in 2026, becoming the second growth curve after the automotive parts sector [1]

Core Viewpoint - UBS forecasts that Tongcheng Travel's core OTA revenue will continue to grow steadily in Q3, with a year-on-year increase of 14%, approaching the previous guidance range of 10-15% [1] Group 1: Revenue Growth - The travel demand during the National Day holiday has become normalized, and UBS believes that Tongcheng's hotel revenue will remain resilient, predicting accommodation revenue growth close to mid-teens level [1] - In terms of transportation business, UBS predicts that Tongcheng's revenue in Q3 will record high single-digit growth year-on-year [1] Group 2: Target Price and Rating - UBS has raised its target price for Tongcheng Travel from HKD 25.5 to HKD 26.5 and maintains a "Buy" rating [1]

Core Viewpoint - Bosideng (03998) has seen a significant increase in stock price, rising by 10.67% to HKD 4.98, with a trading volume of HKD 499 million, driven by favorable weather conditions and positive market analysis [1] Group 1: Weather Impact - The upcoming typhoon "Fengshen" and its associated weather patterns are expected to bring strong winds and rain to South China and the northern South China Sea, which will likely boost demand for winter clothing [1] - Cold air moving south will create a core cooling area in Jiangnan and South China, enhancing the sales environment for winter apparel [1] Group 2: Market Analysis - Shenwan Hongyuan has recommended Bosideng, highlighting that the onset of colder weather will directly benefit the company's winter clothing sales [1] - The Chinese New Year in 2026 falls on February 17, which is 19 days later than in 2025, extending the effective sales window for the peak season and potentially increasing sales volume [1] - The low base from the warm winter of 2024 is expected to facilitate the achievement of sales targets for Bosideng [1] - The market is currently favoring high-dividend assets, and Bosideng has maintained a dividend payout ratio of over 80%, indicating strong future performance and valuation growth [1]

Core Viewpoint - Tsugami Machine Tool China (01651) has seen its stock price increase by over 200% this year, reaching a new high of 35.88 HKD, driven by strong earnings expectations and growth in the machine tool industry [1] Financial Performance - For the first half of the fiscal year 2026 (April-September 2025), the company expects to achieve a net profit attributable to shareholders of 502 million RMB, representing a year-on-year increase of approximately 48% [1] - The board attributes this growth to the ongoing recovery of the domestic economy and the transformation of China's manufacturing sector [1] Industry Trends - The rapid development in user fields such as new energy vehicles and artificial intelligence has created new demand for the machine tool industry [1] - The company has been actively expanding and penetrating various segments of the manufacturing industry, leading to increased demand for its CNC high-precision machine tools [1] Market Position - According to CICC, the company's forecasted profit growth of 48% significantly exceeds the average growth level in the industry, positioning it as a core leader in the recovery of the machine tool sector [1] - The primary downstream market for the company is automotive parts, benefiting from the capital expenditure boom [1] Growth Opportunities - The company is intensifying its layout in the liquid cooling sector, which is expected to open up new growth avenues [1] - It has established cooperation intentions with leading liquid cooling equipment companies, anticipating revenue contributions from this business segment in 2026, marking it as the second growth curve after automotive parts [1]

Core Viewpoint - The report from CMB International maintains a target price of HKD 183 for Kangfang Biopharma (09926) and expresses a long-term bullish outlook with a "Buy" recommendation, highlighting the company's overseas development progress and upcoming catalysts in the next 1-2 years [1] Group 1: Company Performance - Kangfang Biopharma's overseas development is gaining momentum, with significant catalysts expected in the near future [1] - The report notes that Summit Therapeutics has recently announced an expansion of the overseas research scale for Ivosidenib [1] Group 2: Clinical Data - Ivosidenib's second head-to-head Phase III study has yielded strong positive data, showing that the median progression-free survival (PFS) is significantly better than other PD-1 monotherapy drugs [1] - The absolute improvement in PFS for Ivosidenib compared to PD-1 exceeds the improvement seen with traditional chemotherapy [1] Group 3: Sales Expectations - The report maintains an expectation of peak sales in mainland China at RMB 7.1 billion [1]

Group 1 - Jiangsu Hongxin (02625.HK) experienced a decline of over 16% on October 21, 2023, marking a drop of more than 50% from its monthly high [1] - As of the report, the stock price was at 3.59 HKD, with a trading volume of 33.6499 million HKD [1]